Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 5/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10192150 | 0.89 | CYP11B1 (0.56) | CYP11B1CYP11B2NOTUMALDH1A1MAPT | |
| SCHEMBL10192176 | 0.88 | RIPK2 (0.46) | CYP11B1CYP11B2NOTUMALDH1A1JAK2 | |
| SCHEMBL2882290 | 0.84 | MAPT (0.53) | CYP11B1CYP11B2ALDH1A1JAK2TYK2 | |
| SCHEMBL5024162 | 0.80 | POLB (0.58) | CYP11B1CYP11B2NOTUMGAASMN1; SMN2 | |
| SCHEMBL10192217 | 0.77 | CYP11B1 (0.47) | CYP11B1CYP11B2ALDH1A1MAPTGAA | |
| SCHEMBL2882066 | 0.76 | HTR6 (0.47) | CYP11B1CYP11B2ALDH1A1MAPTGAA | |
| SCHEMBL15448559 | 0.76 | NOTUM (0.49) | NOTUMALDH1A1MAPTTP53GLA | |
| SCHEMBL20523685 | 0.75 | RIPK2 (0.45) | CYP11B1CYP11B2ALDH1A1MAPTGAA | |
| SCHEMBL14068908 | 0.75 | CYP11B1 (0.47) | CYP11B1CYP11B2ALDH1A1JAK2TYK2 | |
| SCHEMBL2880426 | 0.73 | PGR (0.52) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | CYP11B1 1044/4885CYP11B2 1209/4885NOTUM 478/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | CYP11B1 1506/4885CYP11B2 1863/4885NOTUM 3153/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | CYP11B1 1506/4885CYP11B2 1863/4885NOTUM 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.